21The transient receptor potential Ankyrin-1 (TRPA1) ion channel is modulated by myriad 22 noxious stimuli that interact with multiple regions of the channel, including cysteine-23 reactive natural extracts from onion and garlic which modify residues in the cytoplasmic 24 domains. The way in which TRPA1 cytoplasmic domain modification is coupled to opening 25 of the ion-conducting pore has yet to be elucidated. The cryo-EM structure of TRPA1 26 revealed a tetrameric C-terminal coiled-coil surrounded by N-terminal ankyrin repeat 27 domains (ARDs), an architecture shared with the canonical transient receptor potential 28 (TRPC) ion channel family. Similarly, structures of the TRP melastatin (TRPM) ion channel 29 family also showed a C-terminal coiled-coil surrounded by N-terminal cytoplasmic 30 domains. This conserved architecture may indicate a common gating mechanism by which 31 modification of cytoplasmic domains can transduce conformational changes to open the 32ion-conducting pore. We developed an in vitro system in which N-terminal ARDs and C-33 terminal coiled-coil domains can be expressed in bacteria and maintain the ability to 34 interact. We tested three gating regulators: temperature; the polyphosphate compound 35 IP 6 ; and the covalent modifier allyl isothiocyanate to determine whether they alter N-and 36 C-terminal interactions. We found that none of the modifiers tested abolished ARD-coiled-37 coil interactions, though there was a significant reduction at 37˚C. We found that coiled-38 coils tetramerize in a concentration dependent manner, with monomers and trimers 39 observed at lower concentrations. Our system provides a method for examining the 40 mechanism of oligomerization of TRPA1 cytoplasmic domains as well as a system to study 41 the transmission of conformational changes resulting from covalent modification. 42 3 43 Introduction 44 The Transient Receptor Potential Ankyrin-1 (TRPA1) ion channel is expressed in 45 nociceptors of the peripheral nervous system [1] where it is activated by a variety of 46 noxious chemical stimuli including electrophilic covalent modifiers [1-3], non-covalent 47 compounds [4], and temperature [5,6]. TRPA1 is also involved in inflammatory signaling [7] 48 and has become an active therapeutic target for treatment of cough [8,9], itch [9,10], and 49 pain [10,11]. 50 Despite the importance of TRPA1 in sensing noxious stimuli, the structural 51 mechanisms of channel activation remain unknown. Since there are multiple channel 52 activators, both covalent and non-covalent, that likely bind to different regions of the 53 channel [3,4,12], it is possible that TRPA1 undergoes different structural rearrangements 54 during activation that depends on the ligand used. Indeed, Cavanaugh, Simkin, and Kim 55 proposed early on that there are different functional states of human TRPA1, one that can 56 be activated by covalent activators in the presence of intracellular polyphosphates and a 57 state that can be activated by Δ 9 -tetra-hydrocannabinol in absence of intracellular 58...